Be part of EORTC’s journey in the fight against cancer

Clinical research is the most important step on the journey from laboratory findings to standard medical practice, and treatments used today are the result of past trials. Since 1962, EORTC diligently works to help cancer patients by setting the bar higher for research design and global standards of cancer research, and to ensure greater and deeper coordination between research groups and partners.

Joining hands means helping advance
the future of cancer therapy

EORTC1634 PersoMed-I study Personalized Risk-Adapted Therapy in Post-Pubertal Patients with Newly-Diagnosed Medulloblastoma, a rare brain tumour

Medulloblastoma predominantly affects children. About 70% of cases occur in patients under 15 years old, with an incidence of 5 cases per million, and an incidence’s peak at 5 years of age. In post-pubertal and adult patients, however, the incidence is about 0.6 cases per million, translating into 450 post-pubertal and adult cases annually in Europe. Predominantly young adults are affected.

Post-pubertal patients all bear an intermediate to high prognostic risk, leading to death and disability in a large part of patients. While treatment has been step-wise developed for children, it has never been optimized for post-pubertal patients in a prospective, randomized way. As such, the most effective treatment with the lowest possible rate of side effects is still unknown in this age group.

Considering the high and uncovered medical and scientific need for research on medulloblastoma in post-pubertal and adult patients, the PersoMed-I consortium initiated the randomized Phase II EORTC 1634 trial with integrated scientific subprojects to better understand medulloblastoma in these age groups.

The EORTC 1634 study trail provides a unique opportunity to investigate highly relevant toxicity and efficacy aspects in a highly under-investigated population with an eminent output for affected patients, clinical and translational research, and society alike.

To find out more on the project or how to support us please contact email us at

Support an EORTC Medical Physics Fellow

Quality assurance in radiotherapy (RTQA) is a key aspect of the treatment of cancer patients using radiotherapy. Its aim is to assess and ensure that the treatment is planned and delivered in an optimal way, leading to improvements in not only the acute and long-term toxicity profiles but also the therapeutic outcome of the treatment.

The aim of a Medical Physics fellowship will be to offer a young medical physics researcher the possibility of being involved in clinical trials focusing on quality improvement in radiation oncology.

The Fellowship will be granted for a 1 year period, extendable to 2 years.

The EORTC Fellowship Programme was established in 1991 to promote European cancer clinical research encouraging physicians, statisticians and scientists from all over the world to stay for up to 3 years at EORTC headquarters in Brussels.

Education Fellows - Illustration
Back to blog

Share This Story

Every month we select one topic to be covered by one of our experts. We’d love to hear from you.



Sign up